Goldman Sachs Group Analysts Give AstraZeneca (AZN) a GBX 4,080 Price Target
Goldman Sachs Group set a GBX 4,080 ($53.31) price target on AstraZeneca (LON:AZN) in a research report released on Thursday. The firm currently has a sell rating on the biopharmaceutical company’s stock.
Several other analysts have also weighed in on the stock. Barclays reiterated an overweight rating on shares of AstraZeneca in a research note on Tuesday, October 9th. Shore Capital reiterated a hold rating on shares of AstraZeneca in a research note on Tuesday, October 16th. Jefferies Financial Group reiterated a hold rating and issued a GBX 5,800 ($75.79) price objective on shares of AstraZeneca in a research note on Friday, October 12th. Credit Suisse Group set a GBX 6,350 ($82.97) price objective on shares of AstraZeneca and gave the company a buy rating in a research note on Thursday, August 30th. Finally, Citigroup reiterated a buy rating and issued a GBX 6,200 ($81.01) price objective on shares of AstraZeneca in a research note on Tuesday, September 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of GBX 5,880.82 ($76.84).
LON:AZN opened at GBX 6,172 ($80.65) on Thursday. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.